InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,727.12
(
-0.10%
)
US TECH 100
19,438.80
(
0.12%
)
Dow Jones
41,968.55
(
-0.57%
)
Brent Oil
73.25
(
-1.76%
)
Bitcoin
63,529.99
(
-1.15%
)
Post# of 1675
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

stock1ace1

Send PM Follow Ignore
Followers 279
Posts 37028
Boards Moderated 2
Alias Born 04/05/2012

stock1ace1

Re: TheFinalCD post# 44

Thursday, 06/22/2017 6:04:08 AM

Thursday, June 22, 2017 6:04:08 AM

Post# of 1675
Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination with standard of care in people with a prior heart attack and inflammatory atherosclerosis. With more than 10,000 patients enrolled in the study over the last six years, CANTOS is one of the largest and longest-running clinical trials in Novartis' history.

D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up